ABSTRACT: A series of novel selenides bearing benzenesulfonamide moieties was synthesized and investigated for their inhibition on six human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms such as the physiologically relevant hCA I, II, VA, VB, VII, and IX and the X-ray complex in adduct with hCA II for some of them investigated. These enzymes are involved in a variety of diseases including glaucoma, retinitis pigmentosa, epilepsy, arthritis, metabolic disorders, and cancer. The investigated compounds showed potent inhibitory action against hCA VA, VII, and IX, in the low nanomolar range, thus making them of interest for the development of isoformselective inhibitors and as candidates for various biomedical applications.
D
iabetes is a chronic disease, and the number of people in the world with the disease has risen from 108 million in 1980 to 422 million in 2014.
1 Several complications of diabetes associated with hyperglycemia lead to disrupt the microvasculature of insulin-insensitive tissues such as the eye, nerve, and brain.
2 These complications are caused by oxidative stress and lead to pericyte loss, 3,4 disruption of the blood−brain barrier (BBB), 5, 6 and cognitive decline. 7−9 The BBB is composed largely of endothelial cells in the microvasculature of the central nervous system. In close proximity to endothelial cells one finds cerebral pericytes, another type of cells vital for the integrity of the BBB. 10 Pericyte cells are especially susceptible to oxidative stress, which leads to cell death by apoptosis. 11 One cause of oxidative stress is the overproduction of superoxide as a byproduct during excess respiration caused by produced influx of glucose in insulin sensitive tissues. 2 Mitochondrial human carbonic anhydrases hCA VA and VB (CAs, EC 4.2.1.1) play a central role in the metabolism of pyruvate, by sustaining the rate of respiration 12 as described in Figure 1 .
Pyruvate is the end-product of the glycolytic pathway obtained by glucose in the cytosol. Pyruvate enters the mitochondria where it is carboxylated to oxaloacetate. In this step, the production of bicarbonate anion required for carboxylation is produced by mitochondrial hCAs through reversible reaction between water and carbon dioxide (CO 2 + H 2 O ⇔ HCO 3 − + H + ). 17 Oxaloacetate, when entering the Krebs cycle, produces FADH 2 and NADH, which are carried out to the electron transfer chain (ETC) to generate ATP. O 2 − is a byproduct of ETC reactions, and it is the precursor of all ROS. The high activity of the Krebs cycle produces a high potential of mitochondrial membrane, which inhibits the transport of electrons to complex III, increasing the half-life of the free radicals of the coenzyme Q and reducing O 2 to O 2 − . Mitochondrial CA isoform VA was identified as one of the major contributors to brain diabetic disease; 13 moreover, it was discover that hCAs IX and XII are recently implicated in ischemia-induced cerebrovascular pathology, 14 making these enzymes attractive drug targets for obtaining agents that can interfere with these deleterious processes. This may lead to novel strategies to prevent diabetic complications in the brain and possibly in other insulin-insensitive tissues. Sulfonamides are the most widely investigated class of CAIs; among these, the most investigated are acetazolamide (AAZ), zonisamide (ZNS), and topiramate (TPM) as pharmacologic inhibitors of mitochondrial hCAs 15−17 as outlined in Figure 2 .
Topiramate, however, had several and serious side effects owing to its ability to inhibit other metabolic pathways, 18, 19 among which, there are nonmitochondrial CA, 20 and in many cases, it is not well tolerated by patients. Thus, it is essential to develop newer drugs with more selectivity and fewer side effects.
Compound Design and Synthesis. The drug design, in this study, starts with the idea to combine the sulfonamide moiety as a typical zinc binding group (ZBG) with the interesting antioxidant propriety of organo-selenium scaffolds. 21−23 In the present study, we investigated different selenides incorporating a benzenesulfonamide moiety as a carbonic anhydrase inhibitor (CAI). The synthetic approach toward the synthesis of diselenide 3 is shown in Scheme 1. The diazonium salt of sulfanilamide was prepared by reaction of 1 with sodium nitrite in the presence of acid (Sandmeyer reaction) and used as a key intermediate for the synthesis of compound 2. Successively, the selenocyanate derivative 2 was converted easily into the diselenide 3 as reported previously by our group 24 and outlined in Scheme 1.
Thereafter, 3 was reduced with NaBH 4 to the corresponding selenolate, which in turn was treated in situ with the appropriate halo-alkyl moieties 4a−j, affording the selenides 5a−j in good yields (Table 1) .
As a further investigation, in order to propose an alternative way to access the target compounds, we sought to achieve selenides from the selenocyanate 2, thus avoiding the synthesis of the diselenide 3. We were pleased to observe that selenides 5a−j were obtained by nucleophilic substitution with the 
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In order to access a different benzenesulfonamide with a seleno aromatic tail (9), the procedure started with synthesized 4-(bromomethyl)benzenesulfonamide 7 as reported in Scheme 3. Compound 7 was synthesized following the method of Naganawa et al. 25 Finally, the selenide 9 was obtained from the reduction of diphenyldiselenide 8 with NaBH 4 and was added in situ to sulfonamide 7 to afford in good yield the selenide 9 as outlined in Scheme 4.
Carbonic Anhydrase Inhibition. In this study was investigated the CA inhibition profile compounds 2, 3, 5a−j, and 9 against six human isoforms such as the physiologically relevant CA I, II, VA, VB, VII, and IX by means of the stoppedflow carbon dioxide hydration assay 26 after a period of 15 min of incubation of the enzyme and inhibitor solutions.
27−31 Their activities were compared to the standard CAIs acetazolamide (AAZ) and topiramate (TPM) ( Table 2) .
One goal of this study was to generate compounds containing organoseleno scaffolds with antioxidant properties to improve selectivity of the targeting of mitochondrial hCA (VA and VB) compared with the clinically used topiramate inhibitor (TPM). For the preliminary investigation, we have tested the key intermediates 2 and 3. We observed that the replacement of a selenocyanate group by a diselenide was well tolerated except for hCA I, so compound 3 displayed a constant of inhibition in the micromolar range (K i = 1522.7 nM). The following structure−activity relationships (SARs) for selenides 5a−j and 9 were observed by analyzing CA inhibition profile in Table 2 . The inhibition profile of hCA I was comparable to standards AAZ and TPM, except for 5d−f and 5i. These compounds showed an activity more than 10 times greater for 5i and over 25 times greater for 5d−f. The other dominant cytosolic isoform, hCA II, was inhibited by almost all selenides with an inhibition constant in the medium nanomolar range, except for compound 5a in the high nanomolar range (K i = 6.3 to 355 nM). An interesting inhibition profile was observed for the mitochondrial isoform hCA VA. All compounds were potent inhibitors with an activity in the low nanomolar range (K i = 2.9 to 8.8 nM). However, the small and cyclic moieties found in 5c, 5d, and 5i led to less active inhibitors. This potency was substantially higher than those for the reported standards; thus, these compounds were excellent candidates for follow-up cell-based studies. In addition, the second mitochondrial isoform hCA VB was also well inhibited by almost all selenides reported here. An interesting case was offered by compound 5a with 5j. The difference in structure is a hydroxyl group versus a methoxy moiety, respectively. However, compound 5a proved to be nearly 10-fold less potent than 5j. The last cytosolic human isoform here studied, hCA VII, was also strongly inhibited by selenides 5a−j with inhibition constants spanning from the subnanomolar (K i = 0.24 nM) to the medium nanomolar range (K i = 27.4 nM). Compound 5a, this time, showed a potency of inhibition 35-fold less than that of the compound incorporating the methoxyl tail (5j). The transmembrane isoform hCA IX was effectively inhibited by all compounds here reported with K i s in the range of 2.2−12 nM. The SAR is almost absent in this case, as all selenides showed a very comparable behavior as potent hCA IX inhibitors. In addition, hCA IX is not only implicated in ischemia-induced cerebrovascular pathology 14 but its expression is upregulated in a wide type of hypoxic tumors. Thus, several of these compounds may have potential as anticancer therapeutics.
Complex of hCA II/Selenides Ligand Complex. The protein complex with compound 5e was determinate by X-ray crystal structure, and we had obtained ligand−protein 
Letter interactions at the atomic level (Figure 3) . hCA II was selected as a model isoform for crystallization because it easily forms crystals, and many studies have been reported on its structure with different classes of inhibitors.
32
Active site analysis of selenide 5e showed that the sulfonamide moiety of inhibitor was tightly coordinated to the Zn(II) ion by a binding mode to the protein similar to other CAIs containing the same ZBG. 32 Additionally, hydrophobic residues that are in relatively close proximity of the inhibitor scaffold are shown around the alkyl chain of compound 5e (Figure 3b) .
Biological Assays. Some selected compounds (3, 5a, 5d, 5h, and 5j), chosen among those possessing an interesting inhibitory profile against the mitochondrial hCA VA and VB, were tested to evaluate their effects on the viability of rat brain endothelial (RBE4) cells, cultured in oxidative stress conditions in the presence of glucose oxidase (GOx). First of all, we evaluated the cytotoxicity of the tested compounds against RBE4, and the cell viability is shown in Figure 4 .
Diselenide 3 was significantly cytotoxic, inducing a mortality of about 50% at a concentration of 30 μM. All other selenides here reported proved to be safe at low concentrations. One should note that a decrease of cell viability was measured at high concentrations (100 μM), after 24 h treatment with compounds 5a and 5h. The safe compounds 5a, 5d, 5h, and 5j were evaluated as possible scavengers of oxidative stress by GOx. RBE4 cells were incubated with glucose oxidase in two concentrations (0.1 and 0.3 U/mL) and selenides, and the results are shown in Figure 5 .
Cell viability of control decreases up to 40% with enhancement of GOx. Among the tested compounds, only selenide 5j showed good protection of cerebral endothelial cells from GOx damage at the higher dose (100 μM). The other selenides did not show any significant scavenger activity in these assay conditions.
Conclusion. We have designed, synthesized, and obtained an X-ray crystallographic structure of a novel series of selenides bearing the benzenesulfonamide moieties, which behave as potent mitochondrial CA inhibitors. Compound 5j proved to be effective as a scavenger agent on RBE4 cell line. Selective binding to mitochondrial CA is an important undertaking for targeting diabetic cerebrovascular pathology and is challenging with classical pharmacologically using sulfonamide/sulfamate CA inhibitors. The findings reported here are of substantial interest and highlight the potential of selenides bearing benzenesulfonamide groups to be exploited for the discovery of potent, mitochondrial-selective CA inhibitors. Thus, in the future we will design new selenides with more selectivity and protector attributes for viability of rat brain endothelial (RBE4) cells. 4 cell/well) were incubated 1 h with GOx (0.1, 0.3 U/mL) and 5a, 5d, 5h, and 5j (10 and 30 μM, also 100 μM, when it was not cytotoxic), and the following 24 h, they recovered in culture medium with the compounds at the same concentrations. **p < 0.01, ***p < 0.001 versus control;^p < 0.05 vs GOX 0.1 U/mL. Author Contributions
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